Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective.
Twenty years ago, antiestrogen therapy with tamoxifen played only a secondary role in breast cancer care. All hopes to cure metastatic breast cancer were still pinned on either the discovery of new cytotoxic drugs or a dose-dense combination of available cytotoxic drugs with bone marrow transplantation. A similar strategy with combination chemotherapy was employed as an adjuvant for primary breast cancer. Simply stated, the goal was to kill the cancer with nonspecific cytotoxic drugs while keeping the patient alive with supportive care. However, medical research does not travel in straight lines, and an alternative approach emerged to solve the problem of controlling tumor growth with minimal side effects: targeted therapy. The approach of using long-term antihormone therapy to control early-stage breast cancer growth would revolutionize cancer care by targeting the tumor estrogen receptor (ER). The success of the strategy would contribute to a decrease in the national mortality figures for breast cancer. More importantly, translational research that targeted the tumor ER with a range of new antiestrogenic drugs would presage the current fashion of blocking survival pathways for the tumor by developing novel targeted treatments. But a surprise was in store when the pharmacology of "antiestrogens" was studied in detail: The nonsteroidal "antiestrogens" are selective ER modulators--ie, they are antiestrogens in the breast, estrogens in the bone--and they lower circulating cholesterol levels. This knowledge would establish a practical approach to breast cancer chemoprevention for women at high risk (tamoxifen) and low risk (raloxifene).
Jordan
V Craig
VC
Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. v.craig.jordan@fccc.edu
Knudson
Alfred G
AG
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D035843:Biomedical Research / Q000639:trends; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D018890:Chemoprevention / Q000639:trends*; D016503:Drug Delivery Systems / Q000639:trends*; D004345:Drug Industry; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*; D017741:Survivors; D013629:Tamoxifen / Q000008:administration & dosage*
D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen